Pfizer Reports Improved Results of P-III OA (A4091056) Study of Tanezumab in Patients with Osteoarthritis (OA)

Shots:

• The P-III OA (A4091056) study involves evaluation of Tanezumab (2.5, 2.5/5 mg SC) vs PBO in 698 patients in ratio (1:1:1) with OA of the knee or hip for 16wks.
• P-III OA (A4091056) study results: WOMAC Pain (-3.2, -3.4 vs -2.6); Reduction from baseline ≥30/50/70/90% (68.0% ,54.5% ,34.6%, 14.7%: 70.4%, 57.1%, 36.5%, 14.2% vs 54.5%, 37.9%, 25.0%, 9.5%); WOMAC physical function (-3.2, -3.5 vs -2.6); PGA-OA (-0.87, -0.90 vs -0.65); RPOA Type 1/2 (1.3%, 0.9%: 0.4%, 0%)
• Tanezumab is a mAb and is jointly co-developed & co-commercialized by Pfizer and Lilly in response to 2013 deal. Lilly to present the above results at ACR/ARHP18

Click here to read full press release/ article | Ref:  Pfizer | Image: NJ